The evolution of radiotherapy techniques in the management of prostate cancer

References

• Kapanen M, Tenhunen M. T1/T2*-weighted MRI provides clinically relevant pseudo-CT density data for the pelvic bones in MRI-only based radiotherapy treatment planning. Acta Oncol 2013;52:612–8.
   PubMed Web of Science ®Google Scholar
• Dinkla AM, Pieters BR, Koedooder K, van Wieringen N, van der Laarse R, van der Grient JN, et al. Improved tumour control probability with MRI-based prostate brachytherapy treatment planning. Acta Oncol 2013;52:658–65.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Hysing LB, Zolnay AG, Söhn M, Hoogeman MS, Muren LP, et al. Adaptive radiotherapy in locally advanced prostate cancer using a statistical deformable motion model. Acta Oncol 2013;52:1423–9.
   PubMed Web of Science ®Google Scholar
• Thor M, Andersen ES, Petersen JB, Sørensen TS, Noe KØ, Tanderup K, et al. Evaluation of an application for intensity-based deformable image registration and dose accumulation in radiotherapy. Acta Oncol 2014;53:1329–36.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Cho KH, Pyo HR, Lee KH, Moon SH, Kim TH, et al. A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol 2013;52:477–85.
   PubMed Web of Science ®Google Scholar
• Henderson RH, Hoppe BS, Marcus RB Jr, Mendenhall WM, Nichols RC, Li Z, et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol 2013;52:463–9.
   PubMed Web of Science ®Google Scholar
• Kil WJ, Nichols RC Jr, Hoppe BS, Morris CG, Marcus RB Jr, Mendenhall W, et al. Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. Acta Oncol 2013;52:492–7.
   PubMed Web of Science ®Google Scholar
• McDonald AM, Jacob R, Dobelbower MC, Kim RY, Fiveash JB. Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer. Acta Oncol 2013;52:1181–8.
   PubMed Web of Science ®Google Scholar
• Lilleby W, Stensvold A, Dahl AA. Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up. Acta Oncol 2014;53:1380–9.
   PubMed Web of Science ®Google Scholar
• Barry AS, Dunne MT, Lyons CA, Finn MA, Moulton B, Taylor JC, et al. Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer. Acta Oncol 2014;53:1390–7.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Tepper JE, Prout GR, Verhey LJ, Mendiondo OA, Goitein M, et al. Proton radiation as boost therapy for localized prostatic carcinoma. JAMA 241:1912–1915, 1979.
   Google Scholar
• Particle Therapy Co-operative Group. Information found at http://www.ptcog.ch/, assessed May 1 2015.
   Google Scholar
• Zietman A. Proton beam and prostate cancer: An evolving debate. Rep Pract Oncol Radiother 2013;18:338–342.
   PubMedGoogle Scholar
• Peeters A, Grutters JP, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010; 95:45–53.
   PubMed Web of Science ®Google Scholar
• Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007;83:110–22.
   PubMed Web of Science ®Google Scholar
• Kole TP, Nichols RC, Lei S, Wu B, Huch SN, Morris CG, et al. A dosimetric comparison of ultra- hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Acta Oncol 2015; 54;825–31.
   PubMed Web of Science ®Google Scholar
• Kole TP, Chen LN, Obayomi-Davis O, Kim JS, Lei S, Suy S, et al. PSA kinetics following robotic Stereotactic Body Radiotherapy for localized prostate cancer. Acta Oncol 2015; 54;832–38.
   PubMed Web of Science ®Google Scholar
• King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217–21.
   PubMed Web of Science ®Google Scholar
• Polders D, Steggerda M, van Herk M, Kiri N, Thelma W, Moonen Luc, et al. Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer. Acta Oncol 2015;54;839–46.
   PubMed Web of Science ®Google Scholar
• Alber M, Thorwarth D. Multi-modality functional image guided dose escalation in the presence of uncertainties. Radiother Oncol 2014;111:354–9.
   PubMed Web of Science ®Google Scholar
• Borren A, Groenendaal G, Moman MR, Boeken Kruger AE, van Diest PJ, van Vulpen M, et al. Accurate prostate tumour detection with multiparametric magnetic resonance imaging: dependence on histological properties. Acta Oncol 2014;53: 88–95.
   PubMed Web of Science ®Google Scholar
• Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, et al. Prostate Cancer RCT Consensus Group. Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol 2014;11:48––91.
   Web of Science ®Google Scholar
• Kiljunen T, Kangasmäki A, Aaltonen A, Kairemo K, Partanen K, Joensuu G, et al. VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases. Acta Oncol 2015;54;847–53.
   PubMed Web of Science ®Google Scholar
• Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol 2015;114:155–60.
   PubMed Web of Science ®Google Scholar
• Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol 2014;20:4220–9.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 2009; 93:14–7.
   PubMed Web of Science ®Google Scholar
• Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature. Eur Urol 2015;67:852–863.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Sadeghi S, Ost P, Vanpachtenbeke F, Vuye P, Lumen N, et al. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. Acta Oncol 2015;54; 854–61.
   PubMed Web of Science ®Google Scholar
• Carl J, Sander L. Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer. Acta Oncol 2015;54;862–67.
   PubMed Web of Science ®Google Scholar
• Cuaron JJ, Harris AA, Chon B, Tsai H, Larson G, Hartsell WF, et al. Anterior-oriented proton beams for prostate cancer: A multi-institutional experience. Acta Oncol 2015;54;868–74.
   PubMed Web of Science ®Google Scholar
• Holmberg L. Can national cancer registration support clinical databases and clinical cancer research? Acta Oncol 2012;51:691–93.
   PubMed Web of Science ®Google Scholar
• Petersen SE, Bentzen L, Emmertsen KJ, Laurberg S, Lundby L, Høyer M. Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer. Radiother Oncol 2014;111:94–9.
   PubMed Web of Science ®Google Scholar
• Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014;106(7). Doi:10.1093/jnci/dju129.
   Google Scholar
• Lennernäs B, Majumder K, Damber JE, Albertsson P, Holmberg E, Brandberg Y, et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol 2015;54; 875–81.
   PubMed Web of Science ®Google Scholar